%0 Case Reports
%T Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
%A Nussbaum PE
%A Nussbaum LA
%A Torok CM
%A Patel PD
%A Yesavage TA
%A Nussbaum ES
%J J Clin Pharm Ther
%V 47
%N 6
%D Jun 2022
%M 35023192
%F 2.145
%R 10.1111/jcpt.13600
%X OBJECTIVE: The BRAF-V600E genetic mutation offers a potential targeted therapy for the treatment of papillary craniopharyngiomas.
METHODS: A 35-year-old man underwent a craniotomy and subtotal resection of a large BRAF-V600E-positive papillary craniopharyngioma before referral to our institution. Our treatment included the BRAF-V600 inhibitor dabrafenib mesylate (75 mg, twice/day) and trametinib dimethyl sulfoxide (2 mg/day). The residual tumour decreased in size by 95% over 21 months without negative side effects.
CONCLUSIONS: We reviewed the literature on BRAF-V600E inhibition as a non-invasive method of treating papillary craniopharyngiomas harbouring the BRAF-V600E mutation.